Laurus Labs Ltd. (LAURUSLABS) Share Price Hits Fresh 52-Week High
- July 30, 2026
- Posted by: Harsh Piplani
- Category: News
Laurus Labs Ltd. Share Price reached a fresh 52-week high of Rs 1,799, up 0.58% today, with a market cap of Rs 94,986.89 crore.
Laurus Labs Ltd. Share Price has reached a fresh 52-week high of Rs 1,799, marking a 0.58% increase from the previous close of Rs 1,781.65. The stock opened at Rs 1,781.8 and experienced a day low of Rs 1,781.65. With a current market capitalization of Rs 94,986.89 crore, Laurus Labs Ltd. is drawing attention in the market. The company’s performance today highlights its potential within the healthcare sector, although the data does not specify a particular catalyst for this price movement.
Laurus Labs Ltd. Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,792 |
| Previous Close | Rs 1,781.65 |
| Today's Change | +Rs 10.35 (+0.58%) |
| Day Open | Rs 1,781.8 |
| Fresh 52-Week High | Rs 1,799 |
| Day Low | Rs 1,781.65 |
| Current Volume | 22,247 |
| Turnover | Rs 3.99 crore |
| Market Capitalisation | Rs 94,986.89 crore |
Laurus Labs Ltd. (LAURUSLABS) traded at Rs 1,792. versus the previous close of Rs 1,781.65, a rise of 0.58%. The stock opened at Rs 1,781.8, reached Rs 1,799, touched Rs 1,781.65. Reported volume was 22,247.
Today, Laurus Labs Ltd. Share Price opened at Rs 1,781.8 and climbed to a fresh 52-week high of Rs 1,799, closing at Rs 1,792. This represents a day change of Rs 10.35 or 0.58%. The stock’s turnover reached Rs 3.99 crore with a volume of 22,247 shares traded, indicating moderate market participation. The price action suggests a positive sentiment, although the specific reasons for the breakout remain unconfirmed.
Laurus Labs Ltd. (LAURUSLABS) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 94,986.89 crore |
| P/E Ratio | 30.28x |
| P/B Ratio | 0.44x |
| ROE | -2.89% |
| ROCE | -0.26% |
Laurus Labs Ltd. was valued at a P/E ratio of 30.28x, a P/B ratio of 0.44x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of -2.89% and ROCE of -0.26%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Benchmark Scope | same sector |
| Company P/E Ratio | 30.28x |
| Benchmark Median P/E | 21.7x |
| Benchmark Average P/E | 68.16x |
| Benchmark P/E Range | 0x to 3,385.56x |
| Company P/B Ratio | 0.44x |
| Benchmark Median P/B | 1.9x |
| Company ROE | -2.89% |
| Benchmark Median ROE | 10.73% |
| Company ROCE | -0.26% |
| Benchmark Median ROCE | 13.2% |
| Company Market Capitalisation | Rs 94,986.89 crore |
| Benchmark Median Market Cap | Rs 138.42 crore |
Laurus Labs Ltd. (LAURUSLABS) is classified under sector: Healthcare.
Laurus Labs Ltd. (LAURUSLABS) has a P/E ratio of 30.28x, which is above the benchmark median of 21.7x, a difference of +39.54%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Laurus Labs Ltd. (LAURUSLABS) has a ROE of -2.89%, which is below the benchmark median of 10.73%, a difference of -126.93%. Laurus Labs Ltd. (LAURUSLABS) has a ROCE of -0.26%, which is below the benchmark median of 13.2%, a difference of -101.97%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Dishman Carbogen Amcis Ltd. | DCAL | 2,856.59 | 30.28 | 0.44 | -2.89 | -0.26 |
| Kwality Pharmaceuticals Ltd. | KPL | 2,686.76 | 40.11 | 8.17 | 28.21 | 26.35 |
| Dr Agarwals Eye Hospital Ltd. | DRAGARWQ | 2,432.22 | 34.7 | 7.02 | -2.6 | 16.92 |
| Sai Parenteral's Ltd. | SAIPARENT | 2,415.06 | 171.06 | 3.16 | 13.9 | 12.97 |
| Beta Drugs Ltd. | BETA | 2,338.9 | 59.68 | 9.44 | 18.65 | 22.17 |
Laurus Labs Ltd. (LAURUSLABS) has a P/E ratio of 30.28x compared with the displayed peer median of 40.11x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of -2.89% compares with a peer median of 13.9% across the companies shown in the table. ROCE stood at -0.26% versus the displayed peer median of 16.92%, providing a capital-efficiency comparison. Laurus Labs Ltd. (LAURUSLABS) has a market capitalisation of Rs 94,986.89 crore. Among the 5 peers shown, 0 have a larger market capitalisation.
Why Investors Are Watching Laurus Labs Ltd.
- Fresh 52-week high at Rs 1,799, indicating positive price action.
- Moderate valuation with a P/E of 30.28 compared to sector benchmarks.
- Negative ROE and ROCE raise concerns about profitability.
- Significant market cap within the healthcare sector.
About Laurus Labs Ltd.
Laurus Labs Ltd. operates in the healthcare sector, focusing on the development and manufacturing of pharmaceutical products. The company is involved in producing active pharmaceutical ingredients (APIs), formulations, and custom synthesis. With a significant market presence, Laurus Labs Ltd. serves a diverse clientele, contributing to its substantial market capitalization. The company’s operations are integral to the pharmaceutical supply chain, positioning it as a key player in the industry.
Track Laurus Labs Ltd. Share Price on Univest
Use Laurus Labs Ltd. (LAURUSLABS) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Investors can track Laurus Labs Ltd. Share Price, technical indicators, fundamental ratios, shareholding patterns, and market insights on Univest. Stay informed about the latest developments and performance metrics.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the current share price of Laurus Labs Ltd.?
Ans. Laurus Labs Ltd. Share Price is currently Rs 1,792, having reached a fresh 52-week high of Rs 1,799 today. The stock moved 0.58% during the session. The intraday range extended from Rs 1,781.65 to Rs 1,799.
What is Laurus Labs Ltd.'s market capitalization?
Ans. Laurus Labs Ltd. has a market capitalization of Rs 94,986.89 crore, positioning it as a significant player in the healthcare sector. The company operates in the Healthcare sector. Its P/E ratio is 30.28x.
How does Laurus Labs Ltd.'s P/E ratio compare to the sector?
Ans. Laurus Labs Ltd.'s P/E ratio of 30.28 is above the sector median of 21.7 but below the sector average of 68.16. The company trades at a P/E ratio of 30.28x.
What are Laurus Labs Ltd.'s profitability metrics?
Ans. Laurus Labs Ltd. has a negative ROE of -2.89% and a negative ROCE of -0.26%, indicating challenges in profitability. ROE stands at -2.89%. ROCE stands at -0.26%. The relevant peer median ROE is 10.73%.
Who are Laurus Labs Ltd.'s peers?
Ans. Peers include Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd., and Dr Agarwals Eye Hospital Ltd., among others. Comparable listed companies include Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd., Dr Agarwals Eye Hospital Ltd.
What is Laurus Labs Ltd.'s P/B ratio?
Ans. Laurus Labs Ltd.'s P/B ratio is 0.44, significantly lower than the sector median of 1.9. The company trades at a P/E ratio of 30.28x. Its P/B ratio is 0.44x. The relevant peer median P/E is 21.7x.
How does Laurus Labs Ltd.'s market cap compare to the sector?
Ans. Laurus Labs Ltd.'s market cap of Rs 94,986.89 crore is substantially higher than the sector average of Rs 460.04 crore. The company operates in the Healthcare sector. Its P/E ratio is 30.28x.
